-

03:51:01 AM

TCRT Stock News

TCRT - Alaunos Therapeutics Inc

05/25/23 5:00 PM

Nasdaq : TCRT

conferencesclinical trial

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood

RHEA-AI

neutral

05/10/23 7:00 AM

Nasdaq : TCRT

earnings

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement with Precigen, Inc.,

RHEA-AI

neutral

05/03/23 8:30 AM

Nasdaq : TCRT

conferencesearnings

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for

RHEA-AI

neutral

04/26/23 12:30 PM

Nasdaq : TCRT

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead

RHEA-AI

neutral

03/30/23 7:00 AM

Nasdaq : TCRT

management

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a

RHEA-AI

very positive

03/29/23 5:30 PM

Nasdaq : TCRT

conferences

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be

RHEA-AI

neutral

03/07/23 7:00 AM

Nasdaq : TCRT

earnings

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enrollment

RHEA-AI

neutral

02/28/23 4:01 PM

Nasdaq : TCRT

conferencesearnings

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on

RHEA-AI

neutral

01/09/23 8:30 AM

Nasdaq : TCRT

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform Increasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting common hotspot

RHEA-AI

positive

11/29/22 9:01 AM

Nasdaq : TCRT

offering

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for

RHEA-AI

neutral

TCRT Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ziopharm.com
Security nameAlaunos Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees105

About Alaunos Therapeutics Inc

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.